Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Adicet Bio Stock Jumps on the Potential of Its Non-Hodgkin's Lymphoma Treatment

Published 06/12/2021, 15:48
Updated 06/12/2021, 15:48
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Shares of Adicet Bio Inc (NASDAQ:ACET) jumped in early Monday trading after it reported positive interim data from its dose escalation int its phase 1 study of a drug for the potential treatment of B-cell Non-Hodgkin’s Lymphoma. 

Adicet shares hit a high of $13.80 at the open and currently trade around $12.88, up 31%.

The company explained that as of November 22, the data cutoff, six patients had been enrolled in the trial for the drug called ADI-001. The first two patients enrolled did not reach the assessment, while three of the four evaluable patients achieved responses, including two complete responses and one partial response that investigators described as a near-complete response.

"Data to-date suggest that ADI-001 is highly clinically active. We look forward to reporting additional data in the first half of 2022 and to rapidly progressing our pipeline to realize the full potential of our gamma delta CAR T cell platform for patients,” commented Chen Schor, president and CEO of Adicet Bio. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.